RCKT241220C30000
- 0.46
- 0.000.00%
Rocket Pharmaceuticals Newsroom
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
Rocket Pharmaceuticals on Track for Lowest Close Since September 2022 -- Data Talk
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $55
Rocket Pharmaceuticals Price Target Maintained With a $39.00/Share by Canaccord Genuity
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Rocket Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Sector Update: Health Care
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $52
Cantor Fitzgerald Remains a Buy on Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals' RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
Rocket Pharmaceuticals to Resume Patient Enrollment in RP-L301 Gene Therapy Phase 2 Trial in 2025
Promising Advancements in Gene Therapy: Buy Recommendation for Rocket Pharmaceuticals
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $51
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $51